ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
GLEEVEC (IMATINIB) MOA
By
Jordan Maire
Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling.
XERMELO MOA
By
admin
XVIVO partnered with Lexicon Pharmaceuticals to create a series of high end medical animations that provide an overview of carcinoid syndrome diarrhea (CSD). The program illustrates how XERMELO, through the inhibition of TPH, turns down the overproduction of serotonin within neuroendocrine tumor cells, helping patients gain control over carcinoid syndrome.
NANOT BIOANIMATION 2020
By
Jordan Maire
Pulsatile blood flow takes you on a ride as a red blood cell through the circulatory system in the Nanot animation. We begin the animation with the role of natural killer (or NK) cells as a part of the innate immune system that defends against cell malfunction as well as foreign particles (like bacteria or viruses). NK cells have a mechanism to identify and destroy damaged or diseased cells.
COBRA PLATFORM MOA
By
admin
Maverick Therapeutics collaborated with the XVIVO team to create a scientific animation that brought to life the highly complex and novel mechanism of action behind Maverick’s pioneering approach to T cell-engaging immunotherapies. A product of brilliant protein engineering, Maverick’s COBRA™ therapeutic platform generates conditionally active bispecific T cell engagers designed to eliminate solid tumors.
BRAIN SHUTTLE
By
admin
The blood-brain barrier (BBB) is a highly selective membrane system that prevents unwanted passage of molecules into the brain extracellular fluid. Consequently, the BBB also significantly hinders the effectiveness of drugs used to treat a number of neurological disorders. Roche has engineered a protein module that can greatly enhance the passage of therapeutic agents across the blood-brain barrier. This 3D medical animation depicts the mechanism by which the “Brain Shuttle” module operates.
GLUTAMATE MODULATION
By
admin
Glutamate is the most abundant excitatory neurotransmitter in the brain. Release of glutamate is essential for normal function of neurons, but the levels of this neurotransmitter must be tightly regulated to avoid toxic effects on neurons. XVIVO partnered with Biohaven to animate the glutamate story.
SB-030 A NOVEL MATRIX REGULATOR
By
admin
XVIVO partnered with Symic Bio to develop an animation that demonstrates the potential efficacy of their molecule, SB-030. SB-030 is delivered to the vessel during a vascular procedure and binds to any exposed matrix inhibiting platelet response to any injury.
PROTAC PLATFORM
By
admin
The biopharmaceutical company Arvinas Inc. has taken a unique approach to develop investigational therapies for hard-to-treat diseases, including cancers. XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases.
LISTERINE SENSITIVITY (PROFESSIONAL)
By
admin
This animation showcases the interplay between the detailed physical structure of channels in the dentin called tubules, the fluid flow inside the tubules, and the signals that propagate from the connected nerves when they are exposed to a trigger such as a drink that is hot, cold, or acidic.
ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
